Hosting Partner

RetInSight develops AI-based software algorithms for use on OCT images in clinical trials, for therapeutic monitoring in clinical routine and diagnostic screening of patients with retinal disease in primary eye care. RetInSight is the first company to introduce MDR CE-certified AI solutions, i.e. clinical decision support systems (CDSS), the RetInSight Fluid Monitor, for monitoring nAMD patients in the EU, CH and UK and the GA Monitor to measure and visualize disease activity and therapeutic efficacy across all aspects including photoreceptor (PR) degeneration defined as EZ (ellipsoid layer) loss, retinal pigment epithelium (RPE) loss and PR/RPE ratio allowing for tracking of disease progression and efficient therapeutic interventions. The GA Monitor identifies fast vs slow progressors at first presentation enabling personalized treatment plans and improve patient outcomes. Not cleared by the FDA, in the US the tools are available for exploratory/research use only . RetInSight also serves as a central AI-based reading center, cAIre, providing the image analysis infrastructure for clinical trial services, offering real-time feed-back to clinical sites and sponsors to support pharmaceutical companies maximizing the value of clinical trial data by fully automated, quantitative, and reproducible read-out, shortening recruitment time and optimizing clinical trial workflows.



Innovation Partner

iCare is a leading company in the global market for ophthalmological devices and software solutions. Icare’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices, fundus imaging devices, perimeters and microperimeters as well as clinical softwares. iCare is a trusted partner in ophthalmic diagnostics (glaucoma, diabetic retinopathy, AMD) and in clinical trials to support the development of new treatments.